VEGFA and cancer: VEGF and other factors are known to recruit EPCs, explaining why reducing angiogenic factors signalling leads to a reduction of EPC mobilization in cancer patients [44]–[46] and why EPC levels rebound concomitantly with a rise of plasma VEGF and other pro-angiogenic cytokines in patients during drug-free intervals of a pan-VEGF inhibition [47].